

Patient ID SA00121629	Patient Name TESTRNV, IMPLEMENTATION	Birth Date 1976-02-15	Gender M	Age 43
Order Number SA00121629	Client Order Number SA00121629	Ordering Physician CLIENT,CLIENT	Report Notes	
Account Information C7028846 DLMP Rochester		Collected 17 Jul 2019 00:00		

Bleeding Diath Prof, Limited

Limited Bleed Prof Interp

Reviewed by

KATHLEEN MEYERS

MCR

Limited Bleed Prof Interp

1 MCR

IMPRESSION: No laboratory evidence of a congenital or acquired plasmatic bleeding diathesis within limitations of current test repertoire.

COMMENTS: Normal screening clotting time tests (prothrombin time and activated partial thromboplastin time) suggest normal plasmatic procoagulant activities. Normal thrombin time excludes presence of heparin and a significant dysfibrinogenemia or hypofibrinogenemia.

Normal von willebrand factor (VWF) antigen and VWF latex immunoassay activity exclude von Willebrand disease (VWD). Normal factor VIII activity and factor XIII screen.

Result Name	Value	Unit	Reference Value	Performing Site
Prothrombin Time (PT), P	11.9	sec	9.4–12.5	MCR
INR	1.1		0.9–1.1	MCR

ADDITIONAL INFORMATION

Standard intensity warfarin therapeutic range: 2.0 to 3.0 High intensity warfarin therapeutic range: 2.5 to 3.5

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
MCR	Mayo Clinic Laboratories - Rochester Main Campus	200 First Street SW, Rochester, MN 55905	William G. Morice M.D. Ph.D	24D0404292

Patient ID SA00121629	Patient Name TESTRNV, IMPLEMENTATION	Birth Date 1976-02-15	Gender M	Age 43
Order Number SA00121629	Client Order Number SA00121629	Ordering Physician CLIENT,CLIENT	Report Notes	
Account Information C7028846 DLMP Rochester		Collected 17 Jul 2019 00:00		

Result Name	Value	Unit	Reference Value	Performing Site
Activated Partial Thrombopl Time, P	36	sec	25-37	MCR
Thrombin Time (Bovine), P	24.9	sec	15.8-24.9	MCR
Fibrinogen, Clauss, P	500	mg/dL	200-500	② MCR
D-Dimer, P	300	ng/mL FEU	≤500	MCR
ADDITIONAL INFORMATION				
D-dimer values less than or equal to 500 ng/mL fibrinogen equivalent units (FEU) may be used in conjunction with clinical pre-test probability to exclude deep vein thrombosis (DVT) and/or pulmonary embolism (PE).				
Coag Factor VIII Activity Assay, P	55	%	55-200	② MCR
Coag Factor IX Assay, P	65	%	65-140	② MCR
Factor XIII(13),Scrn	Normal		Normal	MCR
von Willebrand Factor Ag, P	55	%	55-200	② MCR
von Willebrand Factor Activity, P	55	%	55-200	② MCR

Received: 19 Jul 2019 10:33

Reported: 19 Jul 2019 10:36

Laboratory Notes

- ① This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.
- ② This test has been modified from the manufacturer's instructions. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
MCR	Mayo Clinic Laboratories - Rochester Main Campus	200 First Street SW, Rochester, MN 55905	William G. Morice M.D. Ph.D	24D0404292